MoonLake Immunotherapeutics (MLTX) NASDAQ
17.87
-0.95(-5.05%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
17.87
-0.95(-5.05%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
October 20, 2020
| Name | Title | Pay | Year Born |
| Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO | 787,308 | 1977 |
| Matthias Bodenstedt | Chief Financial Officer | 626,532 | 1988 |
| Kristian Reich | Co-Founder & Chief Scientific Officer | 795,472 | 1966 |
| Nicolas Mosimann | General Counsel | 0 | N/A |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | 0 | N/A |
| Oliver Daltrop | Chief Technical Officer | 0 | N/A |
| Carla Bretes | Director of Investor Relations & External Communications | 0 | N/A |
| Nuala Brennan | Chief Clinical Development Officer | 0 | N/A |
| Joana Cortez | Associate Vice-President of Legal & Compliance | 0 | N/A |
| Luciana Marques | Associate Vice-President of HR, People and Culture | 0 | N/A |
| Roman Akbar-Haase | Chief of Staff to the Executive Board | 0 | N/A |
| Wulf Boecher | Chief Medical Officer | 0 | N/A |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.